Lifestyle
Archived — This article has been archived. The information may be outdated.
Lilly oral GLP-1 posts strong diabetes data
NDTV··10 Jun
Eli Lilly's once-daily oral GLP-1 drug orforglipron, branded Foundayo, showed greater A1C reduction and weight loss than oral semaglutide in Phase 3 diabetes trials. The ACHIEVE-3 study compared two oral GLP-1 receptor agonists in adults with type 2 diabetes.
Prism
What It Means For You
- An effective oral GLP-1 could help patients who avoid injections or struggle with strict dosing rules.
- Better A1C and weight results are promising, but diabetes medicines still require doctor guidance and monitoring.
- Side effects matter because appetite, digestion, hydration and blood sugar changes can affect daily life.
What's Happening
- Eli Lilly reported Phase 3 data for orforglipron in type 2 diabetes.
- The drug outperformed oral semaglutide in A1C reduction and weight loss in the reported head-to-head trial.
- The company is moving toward regulatory filing while studying the drug for several metabolic and weight-related conditions.
GLP-1 Race
- GLP-1 medicines mimic a gut hormone involved in appetite, digestion and blood sugar regulation.
- Many popular GLP-1 drugs are injections, while oral options can improve convenience if they are effective and safe.
- The market is expanding quickly, making comparative data important for doctors, insurers and patients.
all-newstop-stories
